133720-60-2

Basic information

• Product Name: 7-Bromobenzo[b]furan
• Synonyms: 7-Bromobenzo[b]furan;7-BROMOBENZOFURAN;7-Bromo-1-benzofuran
• CAS NO: 133720-60-2
• Molecular Formula: C₈H₅BrO
• Molecular Weight: 197.04
• Mol File: 133720-60-2.mol

Chemical Properties

• Boiling Point: 233.8 °C at 760 mmHg
• Flash Point: 95.2 °C
• Appearance: /
• Density: 1.608g/cm³
• Vapor Pressure: 0.0835mmHg at 25°C
• Refractive Index: 1.638
• Storage Temp.: Refrigerated.
• CAS DataBase Reference: 7-Bromobenzo[b]furan(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Bromobenzo[b]furan(133720-60-2)
• EPA Substance Registry System: 7-Bromobenzo[b]furan(133720-60-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-26-36/37/39
• TSCA: Yes
• Hazardous Substances Data: 133720-60-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
7-Bromobenzo[b]furan is used as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and medications. Its unique chemical structure allows for versatile reactions and modifications, making it a valuable component in the creation of novel therapeutic agents.
Used in Chemical Research:
7-Bromobenzo[b]furan is employed as a significant component in various chemical reactions, facilitating scientific research and development. Its reactivity and stability in different conditions make it an essential tool for exploring new chemical pathways and understanding reaction mechanisms.
Used in Scientific Development:
7-Bromobenzo[b]furan is used as a critical component in the advancement of scientific knowledge, particularly in the fields of organic chemistry and materials science. Its properties and behavior in various reactions provide valuable insights into the design and synthesis of new compounds and materials.
Precautions:
When handling 7-Bromobenzo[b]furan, it is essential to take necessary precautions, as contact with the skin and eyes can cause irritation. Proper protective measures, such as wearing gloves and safety goggles, should be implemented to minimize the risk of adverse effects.

InChI:InChI=1/C8H5BrO/c9-7-3-1-2-6-4-5-10-8(6)7/h1-5H

Upstream product

• 253429-15-1 1-bromo-2-(2,2-diethoxyethoxy)benzene 
• 95-56-7 2-hydroxybromobenzene 
• 591-20-8 3-Bromophenol 
• 204452-94-8 2-(3-bromophenoxy)acetaldehyde diethyl acetal 

Downstream Products

• 35664-72-3 7-phenylbenzofuran 
• 95333-16-7 7-acetylbenzofuran 
• 181819-95-4 1-(benzofuran-7-yl)ethan-1-ol 

Relevant articles and documents

Bipolar fluorescent material based on benzoquinary heterocyclic ring and preparation method thereof and organic electroluminescent device

The present invention discloses a bipolar fluorescent material based on a benzoquinary heterocyclic ring and a preparation method thereof with an organic electroluminescent device, the bipolar fluorescent material having the following structure shown: or

Five-membered heterocyclic oxo carboxylic acid compound and medical application thereof

The invention relates to a five-membered heterocyclic oxo carboxylic acid compound and a medical application thereof. Specifically, the invention relates to a compound, a pharmaceutical salt, a prodrug, a hydrate, a solvate or a crystal form as shown in a formula (I), and also relates to a preparation method of the compound, a pharmaceutical composition containing the compound and an application of the pharmaceutical composition as a secretion regulator of interferon type I, especially as an STING agonist in preparation of medicines for preventing and/or treating I-type interferon related diseases.

Rhodium-Catalyzed Intermolecular Cyclopropanation of Benzofurans, Indoles, and Alkenes via Cyclopropene Ring Opening

The generation of metal carbenoids via ring opening of cyclopropenes by transition metals offers a simple entry into highly reactive intermediates. Herein, we describe a diastereoselective intermolecular rhodium-catalyzed cyclopropanation of heterocycles and alkenes using cyclopropenes as carbene precursors with a low loading of a commercially available rhodium catalyst. The reported method is scalable and could be performed with catalyst loadings as low as 0.2 mol %, with no impact to the reaction yield or selectivity.

Biocatalytic Strategy for Highly Diastereo- and Enantioselective Synthesis of 2,3-Dihydrobenzofuran-Based Tricyclic Scaffolds

2,3-Dihydrobenzofurans are key pharmacophores in many natural and synthetic bioactive molecules. A biocatalytic strategy is reported here for the highly diastereo- and enantioselective construction of stereochemically rich 2,3-dihydrobenzofurans in high enantiopurity (>99.9% de and ee), high yields, and on a preparative scale via benzofuran cyclopropanation with engineered myoglobins. Computational and structure-reactivity studies provide insights into the mechanism of this reaction, enabling the elaboration of a stereochemical model that can rationalize the high stereoselectivity of the biocatalyst. This information was leveraged to implement a highly stereoselective route to a drug molecule and a tricyclic scaffold featuring five stereogenic centers via a single-enzyme transformation. This work expands the biocatalytic toolbox for asymmetric C–C bond transformations and should prove useful for further development of metalloprotein catalysts for abiotic carbene transfer reactions.

1,3-disubstituted ketene compound and application thereof

The invention relates to a 1,3-disubstituted ketene compound with a structure as shown in a formula (I) and application thereof. The compound mainly activates a PPAR (Peroxisome Proliferators-Activated Receptor) alpha, and also has excitation activity for PPPA delta and PPPA gamma. The 1,3-disubstituted ketene compound can be used for treating various diseases related to the PPAR regulation abnormality, such as NASH (nonalcoholic steatohepatitis), and particularly treating nonalcoholic hepatitis, also has potentials for treating diabetes, obesity, fibrotic diseases, cardiovascular diseases (comprising a heart failure, atherosclerosis and the like), kidney diseases (comprising chronic nephrosis, a kidney failure and the like), brain degenerative diseases (comprising the alzheimer disease and the like) and the like, and has higher application value. The formula is shown in the description.

7-process for the preparation of bromide and furan

The invention belongs to the field of organic synthesis, and particularly relates to a preparation method of 7-bromobenzofuran. The preparation method comprises the following steps: reacting ortho-bromophenol and 2-bromo-1,1-dimethoxyethane or 2-chloro-1,

Visible light-induced monofluoromethylenation of heteroarenes with ethyl bromofluoroacetate

Visible light-induced monofluoromethylenation of benzofurans and benzothiophenes with ethyl bromofluoroacetate was developed. This method provided a convenient access to novel α-fluoro-α-heteroarylesters under mild reaction conditions.

SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel spiro-oxadiazoline compounds that are suitable as agonists or partial agonists of a7-nAChR, and pharmaceutical compositions of the same, methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering a spiro-oxadiazoline cx7-nAChR agonist or partial agonist, to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS

Novel tricyclic compounds of Formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing osteoporosis and similar conditions. The compounds are effective as calcium sensing receptor antagonists. Pharmaceutical compositions and methods of treatment are also included.

NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OSTEOPOROSIS

Novel tricyclic compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing osteoporosis and similar conditions. The compounds are effective as calcium sensing receptor antagonists. Pharmaceutical compositions and methods of treatment are also included.